Navigation Links
China Kanghui Holdings Reports Second Quarter 2012 Financial Results
Date:8/21/2012

CHANGZHOU, China, Aug. 21, 2012 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH) ("Kanghui" or the "Company"), a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced its unaudited financial results for the second quarter of 2012.

Second Quarter 2012 Highlights

  • Total net revenue for the second quarter of 2012 increased by 23.6% year-over-year to RMB101.1 million from RMB81.8 million in the corresponding period of the prior year.
  • Gross profit for the second quarter of 2012 increased by 24.0% year-over-year to RMB71.9 million from RMB58.0 million in the corresponding period of the prior year.
  • Operating income for the second quarter of 2012 increased by 27.3% year-over-year to RMB38.7 million from RMB30.4 million in the corresponding period of the prior year.
  • Net income attributable to Kanghui for the second quarter of 2012 increased by 24.7% year-over-year to RMB34.8 million from RMB27.9 million in the corresponding period of the prior year.
  • Non-GAAP[1] net income for the second quarter of 2012 increased by 33.0% year-over-year to RMB39.1 million from RMB29.4 million in the corresponding period of the prior year.
  • Mr. Libo Yang, Chief Executive Officer of the Company, stated, "We are delighted that Kanghui's second quarter marked another strong performance. Growth from trauma and spine sales remained robust, and we further expanded our product offerings by launching our joint reconstruction product into the international markets, while adding another new spine product exclusively marketed in China.  Domestic sales were strong, as we continued to gain momentum throughout China. With unabated strong demand and promising new product launches, we believe we are well positioned for sustained success going forward."

    Ms. Sarah Wang, Chief Financial Officer of Kanghui, commented, "I am proud that Kanghui delivered our eighth consecutive strong quarter since its initial public offering, with our first-ever quarter of recording over RMB 100 million in net revenue. Our outstanding growth in net revenue, along with double-digit growth in key operating metrics, exemplify the strength of our business model.  Benefiting from the strong domestic sales of our proprietary products, our gross profit margins continued to exceed expectations, and as we build on this positive momentum, we are incrementally more confident in outlook for the remainder of 2012."

    Second Quarter 2012 Financial and Operating Results Net revenue increased by 23.6% year-over-year to RMB101.1 million ($15.9 million)[2] in the second quarter of 2012 from RMB81.8 million in the corresponding period of the prior year. 

    Net revenue by product category:Net revenue from trauma products increased by 25.3% year-over-year to RMB59.5 million ($9.4 million) in the second quarter of 2012 from RMB47.5 million in the corresponding period of the prior year. Net revenue from spine products increased by 24.3% year-over-year to RMB32.7 million ($5.1 million) in the second quarter of 2012 from RMB26.3 million in the corresponding period of the prior year. Net revenue from OEM products increased by 11.3% year-over-year to RMB8.9 million ($1.4 million) in the second quarter of 2012 from RMB8.0 million in the corresponding period of the prior year. Joint Reconstruction products initialed sales in June, and generated net revenue of RMB102,000 ($16,000) in the second quarter of 2012.

    Net revenue by geographic markets:Domestic sales of proprietary products increased by 34.7% year-over-year to RMB77.6 million ($12.2 million) in the second quarter of 2012 from RMB57.6 million in the corresponding period of the prior year, while international sales of proprietary products decreased by 8.7% year-over-year to RMB14.7 million ($2.3 million) in the second quarter of 2012 from RMB16.1 million in the corresponding period of the prior year. The decrease in international sales was primarily attributable to the Company's strategic shift in production to fulfill the strong domestic orders, as well as lower sales in the Middle East due to the region's political instability.

    In the second quarter of 2012, cost of revenue increased by 23.2% year-over-year to RMB29.2 million ($4.6 million) from RMB23.7 million in the corresponding period of the prior year. Gross profit increased by 24.0% year-over-year to RMB71.9 million ($11.3 million) in the second quarter of 2012 from RMB58.0 million in the corresponding period of the prior year. Gross margin for the second quarter of 2012 was 71.1%, compared to 71.0% in the corresponding period of the prior year. 

    Selling expenses decreased by 1.7% year-over-year to RMB11.6 million ($1.8 million) in the second quarter of 2012 from RMB11.8 million in the corresponding period of the prior year. General and administrative expenses increased by 28.4% year-over-year to RMB18.1 million ($2.8 million) in the second quarter of 2012 from RMB14.1 million in the corresponding period of the prior year.  Research and development expenses increased by 88.9% year-over-year to RMB3.4 million ($0.5 million) in the second quarter of 2012 from RMB1.8 million in the corresponding period of the prior year.

    Operating income increased by 27.3% year-over-year to RMB38.7 million ($6.1 million) in the second quarter of 2012 from RMB30.4 million in the corresponding period of the prior year. Operating margin increased to 38.3% in the second quarter of 2012 from 37.2% in the corresponding period of the prior year.

    Income tax expense in the second quarter of 2012 was RMB6.5 million ($1.0 million), representing an effective tax rate of 15.8%, compared to an income tax expense of RMB3.8 million, and an effective tax rate of 12.0% in the corresponding period of the prior year.

    Net income attributable to China Kanghui Holdings was RMB34.8 million ($5.5 million) in the second quarter of 2012, representing a year-over-year increase of 24.7% from RMB27.9 million in the corresponding period of the prior year. On a diluted per ADS[3] basis, the Company reported net income per diluted ADS of RMB1.33 ($0.21) in the second quarter of 2012, compared to a net income per diluted ADS of RMB1.09 in the corresponding period of the prior year.Non-GAAP net income, which excludes share-based compensation expenses, increased by 33.0% to RMB39.1 million ($6.2 million) from RMB29.4 million in the corresponding period of the prior year. The Company reported non-GAAP net income per diluted ADS of RMB1.50 ($0.24) in the second quarter of 2012, compared to a non-GAAP net income per diluted ADS of RMB1.11 in the corresponding period of the prior year. 

    During the second quarter of 2012, the Company had a weighted average diluted share count of 156.3 million shares (equivalent to 26.1 million ADSs), compared to 153.7 million shares (equivalent to 25.6 million ADSs) in the corresponding period of the prior year.

    Balance SheetAs of June 30, 2012, the Company had cash and cash equivalents of RMB432.1 million ($68.0 million), compared to RMB380.1 million as of December 31, 2011. As of June 30 2012, the Company held short-term investments of RMB10.3 million ($1.6 million), compared to RMB77.0 million as of December 31, 2011.

    Business OutlookMr. Yang added, "Our solid performance in the first half of 2012 and the recent successful new product launches have set the stage for continued success in the remainder of 2012, providing us with greater comfort in our top line forecast. Moreover, reflecting on our strong gross margins and continuing discipline in optimizing operations and controlling overhead costs, we are slightly raising our full year 2012 guidance for Non-GAAP net income."

    The Company narrows its total net revenue outlook for full year 2012 to be in the range of RMB395 million to RMB403 million, which represents year-over-year growth of 20.8% to 23.3%.  The Company raises its full year 2012 non-GAAP net income to a range of RMB149 million to RMB154 million, from its prior expectation of RMB146 million to RMB153 million.

    This guidance is based on the current market conditions and reflects the Company's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.

    Non-Cash Share-Based Compensation Expenses The Company recognized non-cash share-based compensation expenses of RMB4.4 million ($0.7 million) in the second quarter of 2012.

    The Company classified these non-cash share-based compensation expenses in its costs of revenue, selling expenses, general and administrative expenses as well as in research and development expenses. The break out of these expenses per line item is provided in the financial tables attached to this press release.

    The Company has provided a non-GAAP presentation of results, which excludes the non-cash share-based compensation expenses. Please refer to the non-GAAP presentation provided in the appendix for a year-over-year comparison of non-cash share-based compensation expenses. The Company believes that this non-GAAP presentation is a helpful tool for the Company to plan and forecast future periods and both management and investors benefit from referring to such non-GAAP presentation in assessing the performance of the Company.

    Conference CallKanghui will hold a corresponding conference call and live webcast at 8:00 a.m. ET (8:00 p.m. Beijing Time) on Wednesday, August 22, 2012 to discuss second quarter 2012 results and answer questions from investors.  Listeners may access the call by dialing:US Toll Free:1-866-519-4004US Toll/International:1-718-354-1231Hong Kong Toll Free:800-930-346Hong Kong Toll:852-2475-0994China Toll Free:800-819-0121China Toll Free (Mobile):400-620-8038Conference ID:12464049A replay of the webcast will be accessible through August 29, 2012 on http://ir.kanghui.com or by dialing:

    United States toll free:1-866-214-5335US Toll/International:1-718-354-1232Passcode:12464049About China Kanghui HoldingsFounded in 1997, Kanghui is a leading domestic developer, manufacturer and marketer of orthopedic implants in China. The Company offers a wide array of proprietary orthopedic implant products in trauma, spine and joint reconstruction, and has an extensive nationwide network of distributors for its products in China, as well as in 29 other countries, as of June, 30, 2012. Kanghui has strong research and development capabilities, focused on developing new proprietary products and product lines, and enhancing existing products and product lines. For more information, please visit www.kanghui.com.

    Use of Non-GAAP Financial MeasuresThe Company has included non-GAAP financial measures in this press release. Non-GAAP financial measures are defined as GAAP gross profit excluding non-cash share-based compensation expenses, operating income excluding non-cash share-based compensation expenses, net income excluding non-cash share-based compensation expenses, net margin excluding non-cash share-based compensation expenses, basic earnings per share and per ADS excluding non-cash share-based compensation expenses, and diluted earnings per share and per ADS excluding non-cash share-based compensation expenses. The Company believes that management and investors benefit from referring to the non-GAAP financial measures in assessing the performance of the Company and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. The use of non-GAAP financial measures has limitations and readers should not consider non-GAAP financial measures in isolation from or as alternatives to consolidated financial metrics prepared in accordance with U.S. GAAP. Readers are encouraged to refer to the reconciliation of non-GAAP measures to GAAP measures included herein.

    Safe-Harbor StatementThis press release contains statements of a forward-looking nature, including, among other things, the Company's unaudited operating results for 2012, expected new product introductions, the demand for orthopedic products in China, future prospects of the Company and the ability for the Company to realize its business plans for 2012. These forward-looking statements are not historical facts but instead represent only the Company's belief regarding expected results and events, many of which, by their nature, are inherently uncertain and outside of the Company's control. The actual results and other circumstances of the Company may differ, possibly materially, from the anticipated results and events indicated in these forward-looking statements. Announced results for the second quarter of 2012 are preliminary, unaudited and subject to audit adjustment. Adjustments to the financial statements may be identified when audit work is performed for the year-end audit, which could result in significant differences from this preliminary unaudited financial information. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as "may," "could," "would," "plan," "anticipate," "believe," "estimate," "predict," "potential," "expects," "intends" and "future" or similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management's current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company's control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including the Company's beliefs regarding its strengths and strategies; the Company's ability to expand its international business; the Company's ability to develop and successfully market new products in China and internationally; the Company's current expansion strategy, including its ability to expand its manufacturing and research and development facilities and capabilities and the Company's future prospects, business development, results of operations and financial condition. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's annual report on Form 20-F for the fiscal year 2011, as filed with the Securities and Exchange Commission on April 30, 2012, and are available on the Securities and Exchange Commission's website at www.sec.gov.  For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations, and prospects, please see "Risk Factors" that begins on page 6 of the Company's annual report for fiscal year 2011 and in documents subsequently filed by the Company from time to time with the Securities and Exchange Commission, which can be found on the Company's website at www.kanghui.com or at www.sec.gov.

    Investor Relations Contact InformationAsia Bridge Capital Limited
    Wendy Sun
    Tel: 86-10-8556-9033 (China)
    -888-321-2558 (U.S.)
    Email: wendy.sun@asiabridgegroup.com

     China Kanghui HoldingsSummary - SecondQuarter of 2012(RMB in thousands, except for per share data and per ADS data)Three Months Ended
    June 30,Six Months Ended
    June 30,2011201220112012 Unaudited

     Unaudited  Unaudited

     Unaudited Net revenue

    81,758

    101,101149,733

    183,814Gross profit

    58,049

    71,882106,765

    130,454Non-GAAP gross profit

    58,098

    72,034106,864

    130,639Operating income

    30,374

    38,72160,178

    70,207Non-GAAP operating income

    31,912

    43,08763,133

    77,534Net income attributable to China Kanghui Holdings

    27,879

    34,76649,848

    64,475Non-GAAP net income

    29,417

    39,13252,803

    71,802Earnings per share –basic

    0.20

    0.250.36

    0.46Earnings per share –diluted

    0.18

    0.220.33

    0.41Earnings per ADS –basic

    1.21

    1.482.17

    2.75Earnings per ADS –diluted

    1.09

    1.331.96

    2.49Non-GAAP earnings per share –basic

    0.20

    0.280.38

    0.51Non-GAAP earnings per share -diluted

    0.18

    0.250.35

    0.46Non-GAAP earnings per ADS –basic

    1.23

    1.672.30

    3.06Non-GAAP earnings per ADS -diluted

    1.11

    1.502.08

    2.77- Revenue By Product CategoryTrauma

    47,452

    59,45089,482

    111,022Spine

    26,260

    32,68645,454

    58,579OEM

    8,046

    8,86314,797

    14,111Joint Reconstruction

    -

    102-

    102- Revenue by Business SectorDomestic

    57,633

    77,561107,742

    141,877International

    16,079

    14,67827,194

    27,827OEM

    8,046

    8,86214,797

    14,110



     China Kanghui HoldingsConsolidated Balance Sheets(Expressed in thousands)As of December
     31, 2011As of June 30,
     2012RMBRMB

    US$ Audited  Unaudited

     Unaudited AssetsCurrent assets:Cash and cash equivalents380,092432,055

    68,008Bills receivable5,8734,130

    650Short-term investments76,99810,300

    1,621Accounts receivable, net87,578136,619

    21,505Inventories, net110,907134,280

    21,136Prepayments and other current assets13,42813,521

    2,131Deferred tax assets9,09012,124

    1,908Amount due from related parties5,6724,189

    659Total current assets689,638747,218

    117,618Non-current assets:Property, plant and equipment, net259,825316,325

    49,791Intangible assets, net62,02659,857

    9,422Prepaid land lease payments22,81222,569

    3,552Goodwill155,341155,341

    24,452Long-term investments25,20425,412

    4,000Deposits for non-current assets4,7315,598

    881Deferred tax assets2,4442,335

    368Other assets, non-current25734

    5Total non-current assets532,640587,471

    92,471Total assets1,222,2781,334,689

    210,089Liabilities and equityCurrent liabilities:Accounts payable19,27823,812

    3,748Accrued expenses and other liabilities65,38898,626

    15,524Income tax payable5,8008,594

    1,353Uncertain tax positions4,1974,727

    744Amount due to related parties1,1371,312

    207Total current liabilities95,800137,071

    21,576Non-current liabilities:Deferred government grants6,4093,827

    602Deferred tax liabilities14,85714,474

    2,278Total non-current liabilities21,26618,301

    2,880Total liabilities117,066155,372

    24,456Commitments and contingenciesEquity:Ordinary shares (par value of US$0.001 per share;
    1,000,000,000 shares authorized as of December 31, 2011 and June 30, 2012 (unaudited); 140,401,842 shares issued and outstanding as of December 31, 2011 and 141,204,612 shares issued and outstanding as of June 30, 2012 (unaudited)) 1,0221,027

    162Additional paid-in capital912,972922,625

    145,227Accumulated other comprehensive loss(19,604)(18,954)

    (2,983)Statutory reserves45,41745,417

    7,149Retained earnings156,387220,862

    34,765Total China Kanghui Holdings shareholders' equity1,096,1941,170,977

    184,320Non-controlling interests9,0188,340

    1,313Total equity1,105,2121,179,317

    185,633Total liabilities and equity1,222,2781,334,689

    210,089 

     China Kanghui HoldingsConsolidated Statementsof Comprehensive IncomeExpressed in thousands, except for number of shares and per share data Three Months Ended June 30,  Six Months Ended June 30, 2011201220112012 RMB

     RMB

     US$  RMB

     RMB

     US$  Unaudited

     Unaudited

     Unaudited  Unaudited

     Unaudited

     Unaudited Net revenue81,758

    101,101

    15,914149,733

    183,814

    28,933Cost of revenue

    (23,709)

    (29,219)

    (4,599)(42,968)

    (53,360)

    (8,399)Gross profit58,04971,88211,315106,765130,45420,534Operating expensesSelling expenses

    (11,750)

    (11,648)

    (1,833)(18,738)

    (21,408)

    (3,370)General and administrative expenses

    (14,126)

    (18,131)

    (2,854)(24,548)

    (32,338)

    (5,090)Research and development expenses

    (1,799)

    (3,382)

    (532)(3,301)

    (6,501)

    (1,023)Operating income30,37438,7216,09660,17870,20711,051Interest income

    2,529

    3,274

    5154,248

    7,141

    1,124Government grants

    484

    132

    213,190

    283

    45Other income

    848

    477

    75993

    962

    151Other expenses

    (511)

    (1,471)

    (232)(908)

    (1,828)

    (288)Foreign exchange (loss) gain

    (2,333)

    25

    4(5,341)

    (146)

    (23)Income before income taxes31,39141,1586,47962,36076,61912,060Income taxes

    (3,779)

    (6,498)

    (1,023)(12,761)

    (12,822)

    (2,018)Net income27,61234,6605,45649,59963,79710,042Net loss attributable to non-controlling interests

    267

    106

    17249

    678

    107Net income attributable to China Kanghui Holdings27,87934,7665,47349,84864,47510,149Earnings per share Basic0.20

    0.25

    0.040.36

    0.46

    0.07Diluted0.18

    0.22

    0.040.33

    0.41

    0.07Shares used in earnings per share computationBasic

    138,702,487

    140,757,363

    140,757,363137,770,862

    140,598,892

    140,598,892Diluted

    153,748,894

    156,262,908

    156,262,908152,290,642

    155,615,320

    155,615,320Other comprehensive (loss) income, net of tax[4]Foreign currency translation adjustments

    (271)

    692

    109(474)

    650

    102Total other comprehensive (loss) income, net of tax(271)692109(474)650102Comprehensive income attributable to
    China Kanghui Holdings27,60835,4585,58249,37465,12510,251Share-based compensation charges incurred during
    the period related to:Cost of revenue

    49

    152

    2499

    185

    29Selling expenses

    109

    468

    74221

    604

    95General and administrative expenses

    1,330

    3,604

    5672,537

    6,366

    1,002Research and development expenses

    50

    142

    2298

    172

    27Total1,5384,3666872,9557,3271,153 China Kanghui HoldingsReconciliations of Non-GAAP Results o GAAP Results of Operations(RMB in thousands, except for share, ADS, per share data and per ADS data) Three Months Ended
    June 30,  Six Months Ended
    June 30, 2011201220112012 Unaudited

     Unaudited  Unaudited

     Unaudited Net revenue81,758

    101,101149,733

    183,814Non-GAAP net income29,417

    39,13252,803

    71,802
    Non-GAAP net margin
    36.0%

    38.7%35.3%

    39.1%Share-based compensation(1,538)

    (4,366)(2,955)

    (7,327)GAAP net income27,879

    34,76649,848

    64,475
    GAAP net margin
    34.1%

    34.4%33.3%

    35.1%Non GAAP earnings per share -basic0.20

    0.280.38

    0.51Non GAAP earnings per share -diluted0.18

    0.250.35

    0.46Non GAAP earnings per ADS -basic1.23

    1.672.30

    3.06Non GAAP earnings per ADS -diluted1.11

    1.502.08

    2.77GAAP earnings per share -basic0.20

    0.250.36

    0.46GAAP earnings per share -diluted0.18

    0.220.33

    0.41GAAP earnings per ADS -basic1.21

    1.482.17

    2.75GAAP earnings per ADS -diluted1.09

    1.331.96

    2.49Shares used in computation of:Basic earnings per share138,702,487

    140,757,363137,770,862

    140,598,892Diluted earnings per share153,748,894

    156,262,908152,290,642

    155,615,320Basic earnings per ADS23,117,081

    23,459,56122,961,810

    23,433,149Diluted earnings per ADS25,624,816

    26,043,81825,381,774

    25,935,887Non-GAAP operating income31,912

    43,08763,133

    77,534
    Non-GAAP operating margin
    39.0%

    42.6%42.2%

    42.2%Share-based compensation(1,538)

    (4,366)(2,955)

    (7,327)GAAP operating income30,374

    38,72160,178

    70,207
    GAAP operating margin
    37.2%

    38.3%40.2%

    38.2%Non-GAAP gross profit58,098

    72,034106,864

    130,639
    Non-GAAP gross margin
    71.1%

    71.2%71.4%

    71.1%Share-based compensation(49)

    (152)(99)

    (185)GAAP gross profit58,049

    71,882106,765

    130,454
    GAAP gross margin
    71.0%

    71.1%71.3%

    71.0%[1]  All non-GAAP measures exclude share-based compensation expenses. For further details on non-GAAP measures, please refer to the reconciliation tables and a detailed discussion of the Company's use of non-GAAP information set forth elsewhere in this press release.

     [2]  This announcement contains translations of certain Renminbi ("RMB") amounts into US dollars ("$") at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to US dollars as of and for the quarter ended June 30, 2012 were made at the noon buying rate of RMB6.3530 to $1.00 on June 29, 2012 in the City of New York for cable transfers in Renminbi per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. The Company makes no representation that the Renminbi or US dollar amounts referred to in this press release could have been or could be converted into US dollars or Renminbi, at any particular rate or at all.

     [3]  Each of the Company's American Depositary Shares ("ADS"), which are traded on New York Stock Exchange, represents six of the Company's ordinary shares.

     [4]  Beginning in the first quarter 2012, in accordance with Accounting Standards Update 2011-05, the Company is presenting other comprehensive income and its components in the unaudited condensed consolidated Statement of Comprehensive Income. Other comprehensive income mainly consists of currency translation adjustments relating to the translation of our subsidiaries' financial statements from their functional currency to our reporting currency, which is in the United States dollar. The functional currency of our main subsidiaries in China is the RMB.


    '/>"/>
    SOURCE China Kanghui Holdings
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
    2. CentraState and Freehold Radiology Group train physicians from China
    3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
    4. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
    5. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
    6. China Biologic Products Reports Higher Results for the First Quarter 2012
    7. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
    8. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
    9. China Botanic Attends 67th PHARMCHINA Fair
    10. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
    11. China Botanic Attends the 111th China Import and Export Fair
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
    (Date:4/27/2016)... , April 27, 2016 ... accelerator (MR-linac) platform will be the focal point of ... of the European Society for Radiotherapy & Oncology, taking ... MR-linac integrates a state-of-the-art radiotherapy system and a high-field ... to clearly see the patient,s anatomy in real time. ...
    (Date:4/27/2016)... 27, 2016  Bayer Animal Health today announced ... the University of Florida College of Veterinary Medicine, ... in Communication Award (BECA). Brittany was selected from ... a total of $70,000 in scholarship funds through ... Bayer has provided a total of $232,500 in ...
    Breaking Medicine Technology:
    (Date:4/30/2016)... ... April 30, 2016 , ... ... 2016 questioned the use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ... EOTTS-HyProCure is a minimally invasive procedure performed, when indicated, to correct the ...
    (Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding its Graduate Business ... will be expanding due to high demand: Master of Business Administration (MBA), Master of ... summer. , School of Business Graduate Program Chair Dr. Ray Manganelli said: ...
    (Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
    (Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
    (Date:4/29/2016)... St. Petersburg, Fla. (PRWEB) , ... April 29, ... ... All Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia ... 3,000 babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm ...
    Breaking Medicine News(10 mins):